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Abstract: Upper and lower gastrointestinal dysautonomia
symptoms (GIDS)—sialorrhea, dysphagia, and constipation
are common in Parkinson’s disease (PD) and often socially as
well as physically disabling for patients. Available invasive
quantitative measures for assessing these symptoms and their
response to therapy are time-consuming, require specialized
equipment, can cause patient discomfort and present patients
with risk. The Movement Disorders Society commissioned a
task force to assess available clinical rating scales, critique
their clinimetric properties, and make recommendations
regarding their clinical utility. Six clinical researchers and a
biostatistician systematically searched the literature for scales
of sialorrhea, dysphagia, and constipation, evaluated the
scales’ previous use, performance parameters, and quality of
validation data (if available). A scale was designated ‘‘Recom-
mended’’ if the scale was used in clinical studies beyond the
group that developed it, has been specifically used in PD
reports, and clinimetric studies have established that it is a
valid, reliable, and sensitive. ‘‘Suggested’’ scales met at least
part of the above criteria, but fell short of meeting all. Based
on the systematic review, scales for individual symptoms of
sialorrhea, dysphagia, and constipation were identified along
with three global scales that include these symptoms in the
context of assessing dysautonomia or nonmotor symptoms.
Three sialorrhea scales met criteria for Suggested: Drooling
Severity and Frequency Scale (DSFS), Drooling Rating Scale,
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and Sialorrhea Clinical Scale for PD (SCS-PD). Two dyspha-
gia scales, the Swallowing Disturbance Questionnaire (SDQ)
and Dysphagia-Specific Quality of Life (SWAL-QOL), met
criteria for Suggested. Although Rome III constipation module
is widely accepted in the gastroenterology community, and the
earlier version from the Rome II criteria has been used in a
single study of PD patients, neither met criteria for Suggested
or Recommended. Among the global scales, the Scales for
Outcomes in PD-Autonomic (SCOPA-AUT) and Nonmotor
Symptoms Questionnaire for PD (NMSQuest) both met crite-
ria for Recommended, and the Nonmotor Symptoms Scale
(NMSS) met criteria for Suggested; however, none specifically
focuses on the target gastrointestinal symptoms (sialorrhea,
dysphagia, and constipation) of this report. A very small num-
ber of rating scales have been applied to studies of gastrointes-
tinal-related dysautonomia in PD. Only two scales met ‘‘Rec-
ommended’’ criteria and neither focuses specifically on the
symptoms of sialorrhea, dysphagia, and constipation. Further
scale testing in PD among the scales that focus on these symp-
toms is warranted, and no new scales are needed until the
available scales are fully tested clinimetrically.  2009
Movement Disorder Society
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Dysautonomia-related gastrointestinal symptoms, in-
cluding sialorrhea, dysphagia, and constipation are com-
mon in Parkinson’s disease (PD)1–4 and negatively impact
on patient’ safety and quality of life, yet may not directly
correlate with other parkinsonian motor signs.3,5–7
Although there are ‘‘gold standard’’ techniques for assess-
ing dysphagia (e.g., VFSS or videofluoroscopic swallow-
ing study) and constipation (colonic motility studies),
these measures require specialized equipment and trained
personnel, can be expensive, and may not be readily
available to clinicians and/or researchers. Easily adminis-
tered, validated rating scales that correlate well with the
degree of symptom-related severity and impairment would
be useful for clinicians and researchers. However, much
of the literature evaluating epidemiology of and interven-
tions for sialorrhea, dysphagia, and constipation have
relied on rating scales with limited validation in PD.
METHODS
Administrative Organization and Critique Process
The MDS Task Force on Rating Scales for PD
Steering Committee under its director (C.G.G.) invited
the chairperson (M.L.E.) to form a Writing Committee
and critique rating scales for gastrointestinal-related
autonomic symptoms in PD—specifically, sialorrhea,
dysphagia, and constipation. The committee included
seven movement disorders neurologists and statisticians
with clinimetric expertise from North America and
Europe. Committee members assessed the scales’ pre-
vious use, critiqued clinimetric properties, and made
recommendations regarding their clinical utility. This
report was reviewed by one member of the Steering
Committee (CGG), and after the report was revised, it
was circulated to the full Steering Committee. Once
approved by this group, it was submitted to the Scien-
tific Issues Committee of the MDS and once approved,
submitted for peer-review publication.
Literature Search Strategy
A systematic search was conducted by PUBMED
and Medline (1950–2007) using the combined MeSH
search terms ‘‘SIALORRHEA’’ and ‘‘PARKINSON’S
DISEASE’’ in the English language literature. The
references of the papers retrieved were also systemati-
cally searched for rating scales of sialorrhea. Similarly,
for dysphagia and constipation, the MeSH search
terms ‘‘DYSPHAGIA’’ and ‘‘CONSTIPATION’’ were
combined with ‘‘PARKINSON’S DISEASE,’’ papers
retrieved, examined, and references searched for rating
scales.
Selection of Scales
Scales previously used as outcome measures in stud-
ies of patients with PD were selected for evaluation. If
no such scales were identified, scales used in other
populations were selected for evaluation. In the event,
no scales specifically focusing on the symptoms of
interest (sialorrhea, dysphagia, or constipation) were
identified, general scales that included these symptoms
were considered for evaluation (See Flow Diagram,
Supplementary Material A).
Evaluation of Clinimetric Properties
The following criteria were used to evaluate the
clinimetric properties of the selected scales. (See Sup-
plemental Material B for further details): (1) Content
validity; (2) Readability and comprehension; (3) Inter-
nal consistency; (4) Construct validity; (5) Acceptabil-
ity/floor and ceiling effects; (6) Test-retest reliability;
(7) Agreement; (8) Responsiveness; (9) Interpretability;
(10) Minimal clinically important difference (MCID);
(11) Time to administer; and (12) Administration bur-
den. It should be noted that many validation studies
referenced below employ the Hoehn and Yahr (H&Y)
scale, which is anchored on motor symptoms as a com-
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parator for establishing construct validity. This assumes
that motor symptoms are an anchor for dysautonomia
symptoms in PD, and this assumption may not be
valid. Each selected scale’s performance in these areas
was critiqued and consolidated into a summary of
Advantages and Limitations.
With regard to readability and comprehension, it
should also be noted that validation studies on the
feasibility of translation into a particular language and
clinimetric properties of a scale once translated might
be published in that particular language rather in the
English literature. Our selection method of using Eng-
lish language literature search may therefore have
introduced a selection bias and excluded such studies.
Finally, with regard to responsiveness, none of the
scales specifically addressed the potential variability
introduced by several factors, namely: timing of scale
administration in relation to medication dosing, ‘‘on’’
versus ‘‘off’’ states,8 presence/absence of deep brain
stimulation, patient motivation, presence/absence of
dementia, caregiver input, and circadian factors. Few
interventional studies have been conducted clearly
delineating the sensitivity of scales to these patient
state changes. As these topics were not specifically
addressed in validation studies, we do not address
them below, but would expect investigators to consider
such factors in study designs.
Conclusions
After the evaluation, a scale was rated ‘‘Recom-
mended’’ if it is considered valid, reliable, and sensi-
tive, and is reported in clinical studies beyond the
group that developed it, and if it was applied to PD
populations. Scales rated as ‘‘Suggested’’ met at least
part of the above criteria, but fell short of meeting all.9
RESULTS—EVALUATION AND CRITIQUE
OF SCALES BY SYMPTOM
The reported clinimetric properties for each scale
are summarized in Table 1.
Sialorrhea
Results—Assessment of Sialorrhea in PD
Objective methods for evaluating salivary flow and
volume include saliva collection,24,25 suctioning,26
using a Lashley disk over the parotid (Stenson’s)
duct,12,13 patient based swallowing counts,12,13 or most
commonly, by placing dental cotton pads in the
mouth.26,27–33 These objective tests are too time-con-
suming and impracticable for routine use in the neurol-
ogy clinic and do not quantify the discomfort or social
embarrassment related to sialorrhea.
Many studies on sialorrhea treatment have used Item
no. 6 of the UPDRS to evaluate sialorrhea treatment
responses.29,30,34 Visual Analog Scales (VAS) for sia-
lorrhea frequency and familial and social impact have
been included as outcome measures, but they have not
undergone validity testing (see Supplemental Material
C for details).29,35,36 Three sialorrhea-specific rating
scales were identified for review, but are insufficiently
validated in the PD population:
Drooling Severity and Frequency Scale (See Table
1 for Clinimetric Summary and Supplemental
Material D for Scale Details). Concept Model: The
Drooling Severity and Frequency Scale (DSFS) is a
semiquantitative assessment of the amount of drooling,
has been used in studies of drooling in both cerebral
palsy (CP)10,11 and PD patients.27,34,36 There are two
questions: severity is rated on a five-point scale (never
drools, dry to profuse-drooling off the body, and onto
objects (furniture, books), whereas frequency is rated on
a four-point scale (no drooling to constant drooling).
DSFS Advantages/Limitations: Despite its easy
administration and widespread use, this scale has not
been validated in either CP or PD populations. Further-
more, the DSFS does not address psychosocial impact,
and it is also unclear how well this scale correlates
with objective measures of salivary secretion.
Drooling Rating Scale (See Supplemental Mate-
rial E for Scale Details). Concept Model: The Drool-
ing Rating Scale12,13 was developed in 2001 to evalu-
ate sialorrhea in PD patients. Patients are given a score
from 0 to 3 (‘‘excessive dryness or no excess of sa-
liva’’ to ‘‘continuous drooling, wet clothes, or constant
use of handkerchief or tissue’’) for severity of drooling
over the preceding week in the following situations:
sitting, standing, in bed, talking, and while eating or
drinking.
Drooling Rating Scale Advantages/Limitations:
Although this scale was developed for use in PD
patients, it has not undergone clinimetric evaluation. It
is similar to the DSFS, but evaluates drooling severity
in multiple situations.
Sialorrhea Clinical Scale for PD (See Supplemen-
tal Material F for Scale Details). Concept Model:
The Sialorrhea Clinical Scale for PD (SCS-PD) was
recently developed to address the lack of validated
tools for the evaluation of drooling in PD.14 The SCS-
PD consists of seven questions assessing drooling se-
verity and frequency as well as social and functional
impairment.
637GI DYSAUTONOMIA RATING SCALES IN PD










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SCS-PD Advantages: The SCS-PD scale is specifi-
cally designed for assessing sialorrhea-related discom-
fort in PD patients, and its validity has been prelimi-
narily demonstrated through saliva volume measure-
ments in PD patients and healthy volunteers. With
only seven questions, SCS-PD appears easily adminis-
tered, and therefore has the potential to be adopted as
one of the routine clinical scales for measuring sialor-
rhea-related discomfort in PD patients. Construct valid-
ity was not explicitly discussed in the validation study,
but rating scale correlation with saliva production was
investigated in PD patients and healthy control sub-
jects. Although administration burden was also not spe-
cifically addressed, the scale has only seven questions
and likely imposes only slight burden.
SCS-PD Limitations: Several clinimetric properties
were not addressed in the validation study. In the SCS-
PD, unidimensionality is an important assumption, that
is, all seven questions/items are measuring the same
dimension/factor (the degree of sialorrhea-related dis-
comfort in PD patients). This assumption is critical for
future investigation of the psychometric properties of
this scale. However, no confirmatory factor analysis
(CFA) of this assumption is done in the article. With
regards to readability and comprehension, the SCS-PD
is originally written and administered in Spanish, and
then translated into English. Language translation
might be an important factor that contributes to mea-
surement bias, e.g., differential item functioning (DIF).
The DIF of language has been detected in the
MMSE.37 With regard to acceptability, floor effects
(>15% with lowest possible score) were present in
several of the items. The scale also has problems with
representativeness due to small sample sizes and lack
of demographic information on the sample (race, eth-
nicity, etc). If we assume that the studies were imple-
mented on Hispanics only, then the representativeness
of this sample may be impaired. Additionally, given
the small sample size, it is likely that the results
obtained from this sample cannot be popularized to the
PD patients worldwide properly. Finally, with regard
to interpretability, to ensure the SCS-PD to be a reli-
able scale across diverse populations of PD patients, it
is necessary to do DIF test (Test of possible Measure-
ment Bias) over important demographic characters,
e.g., race, gender, age, education, etc.
Conclusions—Assessment of Sialorrhea in PD
According to the preestablished criteria, DSFS meets
criteria for Suggested because it has been used by mul-
tiple investigators and has been applied specifically to
PD, but does not have adequate clinimetric evaluation
to warrant the ‘‘Recommended’’ designation. The
Drooling Severity Scale meets a weaker level of ‘‘Sug-
gested’’ status because the only criteria it met is previ-
ous use in PD studies. The SCS-PD can also be graded
as ‘‘Suggested’’ because it has demonstrated good in-
ternal consistency and validity and has been applied to
PD patients, although the sample size was small. It has
not been tested by another group beyond the original
report, and therefore falls short of the criteria for
‘‘Recommended.’’
Dysphagia
Results—Assessment of Dysphagia in PD
Although the VFSS evaluation3,4,38 is the ‘‘gold
standard’’ for detecting dysphagia in patients with PD,
only one clinically-based rating scale for dysphagia in
PD was identified.39 Speech pathologists routinely
assess: (1) duration of dysphagia (less than 6 months
vs. more than 6 months), (2) solid versus liquid dys-
phagia, (3) level with which the patients senses food or
fluid ‘‘sticking’’ in their chest, (4) the frequency with
which symptoms occur (constant (with every bite) vs.
intermittent), and (5) whether such associated symp-
toms as melena, regurgitation, vomiting, pain, gastro-
esophageal reflux disease (GERD) symptoms, etc., are
present.
Two reports have evaluated swallowing in relation
to either VFSS or endoscopic swallowing evalua-
tion.15,39 In a multivariate model, Lam et al.15 con-
cluded that three clinical parameters—Hoehn and Yahr
stage, low body mass index, and a positive answer to
the question, ‘‘Do you have trouble keeping food in
your mouth?’’ independently predicted dysphagia on
VFSS. The question regarding keeping food in the
mouth was one of 14 in a swallowing symptoms ques-
tionnaire described by Nathadwarawala et al.40 How-
ever, the sample size in Lam’s study was small and no
formal clinimetric evaluation of the questionnaire in
PD was included in the report. The limited clinimetric
data available from the recent comparison39 of a Swal-
lowing Disturbance Questionnaire (SDQ) to objective
swallowing assessments is discussed later.
Given the paucity of PD-specific dysphagia scales,
other generic scales in the literature were also consid-
ered for critique: dysphagia-specific quality of life and
quality of care scales (SWAL-QOL and SWAL-
CARE)16–19 as well as a functional dysphagia scale
reported by Han et al.41 Because the Han functional
dysphagia scale is based on the VFSS and has limited
validation in stroke patients thus far, we chose not to
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evaluate it further. The SWAL-CARE is directed at
quality of care rather than dysphagia symptom impact
and is not discussed further here. SWAL-QOL is dis-
cussed later. Other dysphagia scales42–44 have not been
extensively validated nor widely used and thus were
not further critiqued here. Within the community of
specialists treating gastrointestinal disorders, specific
criteria for assessing esophageal-related dysphagia (the
Rome III criteria) have been developed20,45,46 via a
delphinian method. However, no published studies
have clinimetrically evaluated these criteria (See Sup-
plemental material C).
Swallowing Disturbance Questionnaire—(See
Supplemental Material G for Scale Details). Con-
cept Model: This questionnaire was developed to use as
a screening tool for dysphagia with hopes of detecting
dysphagia prior to an episode of aspiration pneumonia.
SDQ Advantages/Disadvantages: Internal consis-
tency was very good. Although the time to administer
was not formally assessed, it has 15 questions that
likely would require 10 min or less to administer.
The sample size was relatively small, content validity
was not formally discussed. It is unclear whether patients
as well as experts were consulted in the questionnaire
development. Most clinimetric properties were not
assessed or reported, and further testing of the question-
naire into other languages should be completed.
Generic Scale for Dysphagia-Related Outcomes
(Quality of Life)—SWAL-QOL (See Supplemental
Material H for Scale Details). Concept Model: The
SWAL-QOL is a 44-item dysphagia-specific outcomes
tool that addresses impact on dysphagia-related out-
comes in 10 quality-of-life domains important to
patients—food selection, burden, mental health, social
functioning, fear, eating duration, eating desire, com-
munication, sleep, and fatigue. The conceptual frame-
work is discussed in detail by McHorney.16
SWAL-QOL Advantages: The SWAL-QOL has sev-
eral clinimetric advantages, including good content
validity. Except for fear (Cronbach’s alpha 5 0.79), the
10 domains of SWAL-QOL demonstrated acceptable in-
ternal consistency, suggesting that the scale is appropri-
ate for group-level research. Also, construct validity
(convergent validity) evaluation reveals good agreement
between the dysphagia-specific SWAL-QOL and generic
measures from the MOS (r 5 0.50–0.56).18,47,48 The av-
erage correlation between the SWAL-QOL and generic
measures was almost twice the average correlation
between the SWAL-CARE and generic measures, sug-
gesting good discriminant validity. In evaluating accept-
ability, only ‘‘burden’’ (16%) and ‘‘eating duration’’
(19%) exhibited excess floor effects.49 ‘‘Social function-
ing’’ and ‘‘eating desire’’ ceiling effects were high due to
relatively ‘‘healthy’’ composition of the reported sample
PD patients’ ‘‘relative health’’ may vary more widely
from ‘‘healthy’’ (in samples of patients with H&Y stages
I–II) to ‘‘less healthy’’ (in samples of patients with dis-
ease severity H&Y III–IV), and thus ceiling effects may
not be as high in a PD population.
SWAL-QOL scale is specifically designed for
assessing dysphagia-related impact in patients, and its
validity has been preliminarily proven in varied sam-
ples of patients, including patients with neurodegenera-
tive diseases. Thus, the SWAL-QOL appears to be a
potentially useful scale which would offer more
detailed assessment of the impact of dysphagia symp-
toms in PD.
SWAL-QOL Limitations: Population samples in
which validation studies were completed are largely
English-speaking, white and male, raising readability,
generalizabitity and comprehension issues. As discussed
earlier, language translation might be an important fac-
tor that contributes to measurement bias. Although they
included about 10 to 12% patients with degenerative
neurological conditions, the sample was specifically
selected for patients with static dysphagia problems,
thus interpretability in the PD population may be lim-
ited. Also, if dysphagia associated with PD fluctuates
(as most PD symptoms do), the reported sample may
not have adequate representativeness. With regard to
well-known groups validity, the SWAL-QOL differenti-
ated patients with varying degrees of dysphagia (normal
to tube-feeding dependent), but no information on vary-
ing groups of PD is available. Average time to complete
the SWAL-QOL is slightly longer than the desired 10
min, but the administrative burden is light.
Conclusions-Assessment of Dysphagia in PD
The SDQ is considered as ‘‘Suggested’’ because it has
been tested in a single PD population and some clinimet-
ric data is reported. The SWAL-QOL is considered as
‘‘Suggested’’ because it is not specifically validated in
the PD population, but has been clinimetrically tested in
broad dysphagia populations and performed robustly in
most clinimetric testing. This scale should be studied
further in the PD population because the results of the
validation studies reported to date are promising.
Constipation
Results—Assessment of Constipation in PD
Unlike sialorrhea and dysphagia, which are sign/
symptom complexes, constipation is primarily reported
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as a symptom in movement disorders clinics. It is one of
the most common autonomic symptoms of PD and may
precede diagnosis by decades.50,51 In clinical settings
and the literature, the term ‘‘constipation’’ has a variety
of meanings. Non-PD specific gastrointestinal symptom
questionnaires that focus on constipation in the context
of irritable bowel syndrome52–56 appear to have been
replaced by the Rome criteria and questionnaires.45,57,58
The Rome II criteria59 and subsequent Rome III revi-
sions45,58 (See Supplemental Material I for details) were
developed through international consensus to enable
more consistent evaluation of epidemiology, physiology,
and treatment response of constipation and are widely
accepted in the gastroenterological community. In a pilot
prevalence using the Rome II criteria, Kaye et al.
reported that constipation occurs about three times more
often in patients with PD as in controls.60
Objective measures to investigate constipation in PD
include colon transit study, defecography, anorectal
manometry, and electromyography; however, these
measures require specialized equipment and expertise
and are not commonly available to movement disorders
clinicians and researchers. A variety of questionnaires
have been used in published studies, including: gastro-
intestinal symptom and bowel movement frequency
questionnaires61,62 as well as diaries.63 However, none
of these are validated in the PD population, and only
the most recent60 pilot used Rome criteria or question-
naires. Although the Rome criteria and questionnaires
are widely recognized and accepted within the gastro-
enterological community,57 references specifically
reporting validation procedures for the constipation
module are not published.
Conclusions-Assessment of Constipation in PD
No scales or questionnaires met criteria for ‘‘Sug-
gested’’ or ‘‘Recommended’’ for constipation. The
Rome II Criteria has been recently used in PD litera-
ture to define constipation, but has not been validated
in this population. Given the wide acceptance of the
Rome criteria within the gastroenterology community,
further work is needed to clinimetrically validate the





Although few scales address PD-related sialorrhea,
and no validated questionnaires or scales specifically
address PD-related dysphagia or constipation, more
comprehensive symptom scales that include item rating
the gastrointestinal domain of nonmotor and autonomic
symptoms in parkinsonian disorders for which clini-
metric properties have been reported. They include:
1. The Scales for Outcomes in PD-Autonomic
(SCOPA-AUT),21
2. Nonmotor symptoms questionnaire for PD
(NMSQuest),2
3. Nonmotor Symptoms Scale (NMSS).23
Scales for Outcomes in PDs-Autonomic
(see Supplemental Material J for Scale Details)
Concept Model: This self-administered scale was the
first scale designed to evaluate the presence and fre-
quency of autonomic symptoms in PD. This scale has 25
autonomic symptom-focused items that assess the follow-
ing domains: gastrointestinal (7 items), urinary (6 items),
cardiovascular (3 items), thermoregulatory (4 items),
pupillomotor (1 item), and sexual (2 items for men and
2 items for women). The four response options for each
item range from 0 (never) to 3 (often) with higher total
scores reflecting worse autonomic functioning.
SCOPA-AUT Advantages: The scale has good
content validity. Construct validity—Although the
SCOPA-AUT does not appear correlated with electro-
physiologic autonomic measures,64 SCOPA-AUT has
good known-groups validity and discriminates between
control, mild, moderate, and severe PD groups. The
correlation of the SCOPA-AUT with the HY scale was
satisfactory (rS 5 0.60), ranging from 0.20 to 0.70 for
regions. Well-known groups validity (controls and 3
groups of patients with different severity stages) was
satisfactory. Test-retest reliability/agreement was satis-
factory). Although the time to administer/administra-
tive burden is not specifically stated, estimated time to
complete is 10 min.
SCOPA-AUT Limitations: Internal consistency
responsiveness, MCID, language, and acceptability
were not reported.
Nonmotor Symptoms Questionnaire for PD (See
Supplemental Material K for Scale Details).
Concept model: The PD NMSQuest2,65 is the first
PD-specific, validated, global nonmotor self-adminis-
tered questionnaire and not intended to evaluate the
effect of treatment. NMSQuest is designed to aid clini-
cal management by providing a rapid screening tool
for the presence problematic NMS in PD. The 30
NMSQuest items are scored as ‘‘yes/no’’ and assess 10
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domains. Three of the nine gastrointestinal tract
domain items assess sialorrhea, dysphagia, and consti-
pation.
NMSQuest Advantages: The validation studies
included patients and controls recruited worldwide and
highlight the usefulness of NMSQuest in 545 PD
patients across all stages.23,66 Content validity was
appropriate and readability and comprehension were
formally assessed; both patients and caregivers demon-
strated high rates of agreement (92–100%) that the
questions were clearly worded. The correlation of the
NMSQuest with the HY scale was satisfactory (rS 5
0.31, P 5 0.006), suggesting good construct validity.
As an assessment tool, floor/ceiling effects were not
evaluated. However, the response distribution by PD
patients and age matched controls reveal that the ques-
tionnaires as a whole and the questions on sialorrhea,
dysphagia, and constipation have good discriminant
properties. The NMSQuest appears to correlate well
with disease progression, indicating good responsive-
ness and interpretability. Administrative burden is low.
NMSQuest Limitations: Internal consistency, test-
retest reliability/agreement were not evaluated. MCID
was also not addressed as the NMSQuest is intended
as an evaluation tool, not a tool to assess changes in
response to treatment.
Nonmotor Symptoms Assessment Scale for PD (See
Supplemental Material L for Scale Details).
Concept model: To provide a method to quantify
NMS, the NMSS was developed.23 This scale is di-
vided in nine major domains containing 30 questions
(See Supplementary Material K). The NMSS reflects
the questions flagged in the NMSQuest and is aimed to
be a practical measure for use by health professionals.
Item scoring is obtained by multiplying the severity
score (ranging 0–3) and the frequency score (ranging
1–4). The scale can, therefore, capture symptoms that
are severe but relatively infrequent (e.g., hallucina-
tions) and those less severe but persistent (e.g., consti-
pation, fatigue, or low mood).
NMSS Advantages: Content validity was excellent.
Clinical use of the NMSS as judged from validation
study suggests that the scale can be used in a clinic set-
ting and effectively translated to non-English-speaking
patients. The testing hypothesis for construct validity
was clearly stated and the scale performed adequately.
Test-retest reliability/Agreement—Although the ICC
for dysphagia was below 0.70, it was high for the other
GI symptom questions (0.96–0.99) and the overall GI
tract domain (0.84). Responsiveness and Interpretability,
the NMSS appears correlates moderately well with dis-
ease severity/progression as measured by the UPDRS III
and H&Y scores (Spearman coefficient 0.33–0.35). Cor-
relation with the NMSQuest and PDQ-8 was excellent (r
5 0.7). MCID was estimated in part by examining the
standard error or the mean (SEM) and standard deviation
(SD). In the gastrointestinal domain (where the ICC was
high), the SEM was less than [1/2] the SD. The gastroin-
testinal domain was specifically maintained because it
addresses clinically relevant symptoms of ‘‘saliva drib-
bling", dysphagia, and constipation. The questionnaire is
moderately easy to score and has moderate administra-
tive burden. The NMSS has good clinimetrics in spite of
complex construct and correlates modestly with motor
measures and disease duration and closely with quality
of life and NMSQuest.
NMSS Limitations: Internal consistency for the
whole NMSS was acceptable though the gastrointesti-
nal domain showed weak internal consistency. The
scale as a whole demonstrates good acceptability,
although the floor and ceiling effects for the gastroin-
testinal domain were not reported. It has not yet been
reported in studies other than the validation study.
Conclusions-Global Scales Addressing
Dysautonomia and Nonmotor Symptoms
According to the preestablished criteria, the SCOPA-
AUT and NMSQuest may be considered ‘‘Recom-
mended’’ because they have been clinimetrically tested
with success and reported in studies outside the origi-
nal validation study.64,66 NMSS may be considered
‘‘Suggested’’ because it has been clinimetrically exam-
ined and specifically studied in PD, but has not yet
been reported outside the original study.64,66
PD-specific scales for such isolated symptoms as dys-
phagia are lacking, and there are specific PD scales for
the whole autonomic spectrum, but clinimetric properties
have been demonstrated for global nonmotor scales.
Such global scales as the SCOPA-AUT or questionnaires
as the NMSQuest may, therefore, be used for assessing
the presence and frequency of dysphagia symptoms.
Both the SCOPA-AUT and the NMSQuest, as part of a
holistic measure of nonmotor symptoms of PD, specifi-
cally provide standardized measures for the presence or
absence of sialorrhea, constipation, and dysphagia.
RESULTS AND CONCLUSIONS—SINGLE
ITEMS FROM COMPREHENSIVE SCALES
Single items addressing each symptom within the
context of a comprehensive scale include UPDRS Item
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no. 6 for sialorrhea, UPDRS Item no. 7, UMSARS
Item no. 2 for dysphagia, and UMSARS Item no. 12
for constipation.
Clinimetric properties for the UPDRS as a whole are
established, and the original concept was the UPDRS
would be a core assessment tool, supplemented by
individual scales or measures that were focused on spe-
cific outcomes of interest.67 As such, clinimetric evalu-
ations of individual items are more limited. However,
both Item no. 6 (for sialorrhea) and no. 7 (for swallow-
ing) had excellent interobserver reliability, even when
self-administered.68
Similarly, UMSARS was specifically designed to be
applied in Multiple System Atrophy as an equivalent
to the UPDRS for PD.22 As such, it has not been spe-
cifically tested in PD, but it still would have validation
clinimetric data in the primary condition. However, it
is not specifically focused nor weighted on dysautono-
mia, and there is no clinimetric data on the cluster of
gastrointestinal symptoms.
CONCLUSIONS AND RECOMMENDATIONS
c There are remarkably few scales or questionnaires
specifically focusing on sialorrhea, dysphagia, and
constipation in PD (Table 2).
c Although commonly used, VAS scales have not
been validated. However, given this frequency with
which VAS scales are used in sialorrhea and other
gastrointestinal dysautonomia symptoms (GIDS)
research as outcome measures and their ease of
administration, we strongly recommend a particular
VAS scale be clinimetrically validated before
including it as a primary outcome measure.
c Depending on the situation, broader, nonmotor
scales (SCOPA-AUT and NMSQuest) may offer
a method of quickly ascertaining presence and
frequency of sialorrhea, dysphagia, and constipa-
tion, but may have limited ability to quantitative
changes.
c Of the existing scales, most have not been validated
or have not been fully validated (DSFS, SWAL-
QOL, Rome III) in parkinsonian patients.
c The NMSS has recently been developed and may
offer a global tool for evaluating response to therapy
for NMS, but has not yet been widely used.
c Quantitation of severity, symptom progression, and
response to interventions for sialorrhea, dysphagia,
and constipation in clinical studies should probably
include physiological measures (e.g., VFSS for dys-
phagia) until more detailed rating scales can be vali-
dated and/or developed.
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